{"id":31954,"date":"2019-02-25T11:33:17","date_gmt":"2019-02-25T10:33:17","guid":{"rendered":"https:\/\/www.unither-pharma.com\/?post_type=publication&p=31954"},"modified":"2026-03-18T15:52:08","modified_gmt":"2026-03-18T14:52:08","slug":"technologies-de-liberation-des-medicaments-un-levier-cle-pour-offrir-un-avantage-concurrentiel","status":"publish","type":"publication","link":"https:\/\/www.unither-pharma.com\/fr\/publication\/technologies-de-liberation-des-medicaments-un-levier-cle-pour-offrir-un-avantage-concurrentiel\/","title":{"rendered":"Les nouvelles formes d\u2019administration : un levier strat\u00e9gique pour am\u00e9liorer l\u2019usage des m\u00e9dicaments"},"content":{"rendered":"

Les <\/span>technologies d\u2019administration des m\u00e9dicaments<\/strong> (formes gal\u00e9niques) offrent un <\/span>avantage concurrentiel<\/strong> aux laboratoires : elles r\u00e9pondent mieux aux besoins des <\/span>patients<\/strong>, des <\/span>m\u00e9decins<\/strong>, des <\/span>infirmiers<\/strong> et des <\/span>pharmaciens<\/strong>, tout en cr\u00e9ant de la valeur pour l\u2019ensemble du <\/span>syst\u00e8me de sant\u00e9<\/strong>.<\/span><\/p>\n

\n

En reformulant<\/strong> des actifs existants en formes de dosage plus pratiques<\/strong>, les laboratoires de marques<\/strong> d\u00e9fendent leurs franchises, les g\u00e9n\u00e9riqueurs<\/strong> am\u00e9liorent des produits \u00e9tablis, et les acteurs OTC<\/strong> se diff\u00e9rencient sur des march\u00e9s tr\u00e8s comp\u00e9titifs \u2014 tout en am\u00e9liorant l\u2019observance<\/strong> et l\u2019exp\u00e9rience patient.<\/p>\n

<\/h2>\n

1) Formulations centr\u00e9es sur le patient : valeur clinique et march\u00e9<\/strong><\/h2>\n

1.1. Innovations gal\u00e9niques au service de l\u2019usage<\/strong><\/h3>\n
    \n
  • Doses pr\u00e9mesur\u00e9es<\/strong> : sticks liquides, formats \u201con\u2011the\u2011go\u201d pour int\u00e9grer la prise au quotidien.<\/li>\n
  • Poudres orales \/ sticks poudre<\/strong> : transport facile, reconstitution rapide.<\/li>\n
  • Comprim\u00e9s orodispersibles (ODT)<\/strong> : adapt\u00e9s aux troubles de d\u00e9glutition<\/strong> (p\u00e9diatrie, g\u00e9riatrie).<\/li>\n
  • Go\u00fbt masqu\u00e9 \/ enrobage particulaire<\/strong> : am\u00e9liore l\u2019acceptabilit\u00e9 et l\u2019observance th\u00e9rapeutique<\/strong>.<\/li>\n
  • Lib\u00e9ration prolong\u00e9e (LP\/ER)<\/strong> : espacement des prises, meilleure tol\u00e9rance.<\/li>\n<\/ul>\n

    Mots\u2011cl\u00e9s int\u00e9gr\u00e9s<\/strong> : formes gal\u00e9niques, technologies d\u2019administration, comprim\u00e9s orodispersibles, sticks liquides, go\u00fbt masqu\u00e9, lib\u00e9ration prolong\u00e9e, observance<\/em>.<\/p>\n

    1.2. Diff\u00e9renciation et gestion du cycle de vie<\/strong><\/h3>\n
      \n
    • G\u00e9n\u00e9riques<\/strong> : se diff\u00e9rencier<\/strong> dans des march\u00e9s satur\u00e9s via des formulations \u00e0 valeur ajout\u00e9e<\/strong>.<\/li>\n
    • OTC<\/strong> : premiumisation<\/strong> par des formats pratiques et centr\u00e9s patient<\/strong>, moins sensibles \u00e0 la guerre des prix.<\/li>\n
    • Rx (marques)<\/strong> : life\u2011cycle management<\/strong> avant\/pendant\/ apr\u00e8s l\u2019expiration des brevets<\/strong> (protection PI additionnelle, meilleure exp\u00e9rience).<\/li>\n<\/ul>\n

      \u00ab Les m\u00e9dicaments \u00e0 valeur ajout\u00e9e sont une excellente occasion de diff\u00e9rencier<\/strong> notre portefeuille \u00bb, souligne Robert Knerr (Stada)<\/strong>.<\/p><\/blockquote>\n

      <\/h2>\n

      2) Identifier les opportunit\u00e9s : \u00e9couter le terrain, cartographier les usages<\/strong><\/h2>\n

      2.1. Intelligence \u201cpoint de soins\u201d<\/strong><\/h3>\n
        \n
      • Collecte terrain<\/strong> : m\u00e9decins, infirmiers, pharmaciens, patients<\/strong>.<\/li>\n
      • Groupes consultatifs et panels experts\/patients<\/strong> pour qualifier la valeur per\u00e7ue<\/strong> vs valeur r\u00e9elle<\/strong>.<\/li>\n
      • Analyse locale<\/strong> : attentes variables selon pays \/ pratiques cliniques.<\/li>\n<\/ul>\n

        Markus Weigandt (Merck KGaA)<\/strong> : \u00ab Votre innovation r\u00e9pond\u2011elle \u00e0 un besoin important<\/strong> ? \u00bb<\/p><\/blockquote>\n

        Mots\u2011cl\u00e9s<\/strong> : retour d\u2019exp\u00e9rience patient, insights prescripteurs, adoption clinique, valeur per\u00e7ue<\/em>.<\/p>\n

        2.2. Indications propices aux formats \u201con\u2011the\u2011go\u201d<\/strong><\/h3>\n
          \n
        • Analg\u00e9siques, antihistaminiques, antiacides<\/strong> : sympt\u00f4mes impr\u00e9dictibles<\/strong>, besoin de prise rapide et discr\u00e8te<\/strong>.<\/li>\n
        • Formats poudre \/ liquide<\/strong> = disponibilit\u00e9 permanente + administration facilit\u00e9e.<\/li>\n<\/ul>\n

          2.3. Sources d\u2019id\u00e9es : brevets, CDMO, open innovation<\/strong><\/h3>\n
            \n
          • Veille brevets<\/strong> (fin de protection) \u2192 opportunit\u00e9s de reformulation<\/strong>.<\/li>\n
          • CDMO pharmaceutiques<\/strong> : acc\u00e8s multi\u2011technologies, acc\u00e9l\u00e9ration<\/strong> et r\u00e9duction co\u00fbts<\/strong>.<\/li>\n
          • Approche agnostique<\/strong> (interne\/externe) : \u201con regarde la qualit\u00e9 de l\u2019id\u00e9e\u201d<\/em>.<\/li>\n<\/ul>\n

            3) CDMO : le partenaire cl\u00e9 de l\u2019innovation gal\u00e9nique<\/strong><\/h2>\n

            3.1. Pourquoi externaliser ?<\/strong><\/h3>\n
              \n
            • Couvrir les lacunes technologiques<\/strong> internes.<\/li>\n
            • Acc\u00e9der \u00e0 des plateformes sp\u00e9cialis\u00e9es<\/strong> (ODT, LP, micro\u2011encapsulation, go\u00fbt masqu\u00e9).<\/li>\n
            • Time\u2011to\u2011market<\/strong> r\u00e9duit, capex<\/strong> limit\u00e9.<\/li>\n<\/ul>\n

              Sandoz<\/strong> : \u00ab On ne peut pas exceller dans tous les domaines. \u00bb<\/p><\/blockquote>\n

              3.2. Crit\u00e8res de s\u00e9lection d\u2019un CDMO<\/strong><\/h3>\n
                \n
              • Fiabilit\u00e9, qualit\u00e9, conformit\u00e9<\/strong> (GxP, dossiers r\u00e9glementaires).<\/li>\n
              • Expertise technologique<\/strong> et preuves (r\u00e9f\u00e9rences, lots cliniques\/commerciaux).<\/li>\n
              • Capacit\u00e9s industrielles<\/strong> (scale\u2011up, validation, approvisionnement).<\/li>\n
              • Culture projet \/ co\u2011d\u00e9veloppement<\/strong>.<\/li>\n<\/ul>\n

                \u00c0 retenir<\/strong> : la taille<\/strong> du CDMO est secondaire ; la capacit\u00e9 \u00e0 d\u00e9livrer<\/strong> prime.<\/p>\n

                 <\/p>\n

                4) Du concept au succ\u00e8s march\u00e9 : aligner valeur et adoption<\/strong><\/h2>\n

                4.1. March\u00e9 Rx : convaincre des d\u00e9cideurs multiples<\/strong><\/h3>\n
                  \n
                • Payeurs\/acheteurs centralis\u00e9s<\/strong>, logique de co\u00fbts<\/strong> parfois > valeur d\u2019usage.<\/li>\n
                • Incitations terrain paradoxales (ex. injections vs formes plus pratiques).<\/li>\n
                • N\u00e9cessit\u00e9 d\u2019un dossier de valeur<\/strong> : observance, QdV, r\u00e9sultats cliniques, co\u00fbt global.<\/li>\n<\/ul>\n

                  4.2. March\u00e9 OTC : p\u00e9dagogie et notori\u00e9t\u00e9<\/strong><\/h3>\n
                    \n
                  • D\u00e9cision directe<\/strong> du consommateur\u2026 \u00e0 condition qu\u2019il connaisse<\/strong> la forme.<\/li>\n
                  • Sticks\u2011packs<\/strong> : notori\u00e9t\u00e9 encore faible \u2192 besoin de formation officinale<\/strong> + visuels usage<\/strong> + essais<\/strong>.<\/li>\n
                  • Marque<\/strong> = levier critique pour vendre des am\u00e9liorations progressives<\/strong>.<\/li>\n<\/ul>\n

                    <\/h2>\n

                    5) Tendances & perspectives : l\u2019essor des formes centr\u00e9es patient<\/strong><\/h2>\n

                    5.1. Syst\u00e8mes de sant\u00e9 plus ouverts \u00e0 la valeur d\u2019usage<\/strong><\/h3>\n
                      \n
                    • Pays nordiques : prise en compte de la voix du patient<\/strong> et du terrain dans les achats.<\/li>\n
                    • Int\u00e9gration des b\u00e9n\u00e9fices de commodit\u00e9<\/strong> et QdV<\/strong> dans les d\u00e9cisions.<\/li>\n<\/ul>\n

                      5.2. Observance = r\u00e9sultats<\/strong><\/h3>\n
                        \n
                      • Des formes simples et pratiques<\/strong> am\u00e9liorent l\u2019observance th\u00e9rapeutique<\/strong> \u2192 meilleurs r\u00e9sultats<\/strong> et co\u00fbts \u00e9vit\u00e9s<\/strong>.<\/li>\n
                      • Message cl\u00e9 dans les dossiers m\u00e9dico\u2011\u00e9conomiques<\/strong>.<\/li>\n<\/ul>\n

                        5.3. Ce qui va acc\u00e9l\u00e9rer<\/strong><\/h3>\n
                          \n
                        • Pression concurrentielle \u2192 diff\u00e9renciation gal\u00e9nique<\/strong>.<\/li>\n
                        • OTC<\/strong> : formats \u201con\u2011the\u2011go<\/strong>\u201d, ODT<\/strong>, go\u00fbt masqu\u00e9<\/strong>.<\/li>\n
                        • Rx<\/strong> : LP\/ER<\/strong>, combinaisons, gestion post\u2011brevet<\/strong>.<\/li>\n
                        • CDMO<\/strong> : r\u00f4le accru dans le co\u2011d\u00e9veloppement<\/strong>.<\/li>\n<\/ul>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

                          Les technologies d\u2019administration des m\u00e9dicaments (formes gal\u00e9niques) offrent un avantage concurrentiel aux laboratoires : elles r\u00e9pondent mieux aux besoins des patients, des m\u00e9decins, des infirmiers et des pharmaciens, tout en cr\u00e9ant de la valeur pour l\u2019ensemble du syst\u00e8me de sant\u00e9. En reformulant des actifs existants en formes de dosage plus pratiques, les laboratoires de marques […]<\/p>\n","protected":false},"featured_media":0,"menu_order":0,"template":"","meta":{"_acf_changed":false},"topic":[199],"media_type":[158],"class_list":["post-31954","publication","type-publication","status-publish","hentry","topic-sante","media_type-livre-blanc"],"acf":[],"yoast_head":"\nLes nouvelles formes d\u2019administration : un levier strat\u00e9gique pour am\u00e9liorer l\u2019usage des m\u00e9dicaments | Unither<\/title>\n<meta name=\"description\" content=\"Les nouvelles formes d\u2019administration : un levier strat\u00e9gique pour am\u00e9liorer l\u2019usage des m\u00e9dicaments | Unither\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.unither-pharma.com\/fr\/publication\/technologies-de-liberation-des-medicaments-un-levier-cle-pour-offrir-un-avantage-concurrentiel\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Les nouvelles formes d\u2019administration : un levier strat\u00e9gique pour am\u00e9liorer l\u2019usage des m\u00e9dicaments | Unither\" \/>\n<meta property=\"og:description\" content=\"Les nouvelles formes d\u2019administration : un levier strat\u00e9gique pour am\u00e9liorer l\u2019usage des m\u00e9dicaments | Unither\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.unither-pharma.com\/fr\/publication\/technologies-de-liberation-des-medicaments-un-levier-cle-pour-offrir-un-avantage-concurrentiel\/\" \/>\n<meta property=\"og:site_name\" content=\"Unither\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-18T14:52:08+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@UnitherPharma\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.unither-pharma.com\/fr\/publication\/technologies-de-liberation-des-medicaments-un-levier-cle-pour-offrir-un-avantage-concurrentiel\/\",\"url\":\"https:\/\/www.unither-pharma.com\/fr\/publication\/technologies-de-liberation-des-medicaments-un-levier-cle-pour-offrir-un-avantage-concurrentiel\/\",\"name\":\"Les nouvelles formes d\u2019administration : un levier strat\u00e9gique pour am\u00e9liorer l\u2019usage des m\u00e9dicaments | Unither\",\"isPartOf\":{\"@id\":\"https:\/\/www.unither-pharma.com\/fr\/#website\"},\"datePublished\":\"2019-02-25T10:33:17+00:00\",\"dateModified\":\"2026-03-18T14:52:08+00:00\",\"description\":\"Les nouvelles formes d\u2019administration : un levier strat\u00e9gique pour am\u00e9liorer l\u2019usage des m\u00e9dicaments | Unither\",\"breadcrumb\":{\"@id\":\"https:\/\/www.unither-pharma.com\/fr\/publication\/technologies-de-liberation-des-medicaments-un-levier-cle-pour-offrir-un-avantage-concurrentiel\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.unither-pharma.com\/fr\/publication\/technologies-de-liberation-des-medicaments-un-levier-cle-pour-offrir-un-avantage-concurrentiel\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.unither-pharma.com\/fr\/publication\/technologies-de-liberation-des-medicaments-un-levier-cle-pour-offrir-un-avantage-concurrentiel\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.unither-pharma.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Les nouvelles formes d\u2019administration : un levier strat\u00e9gique pour am\u00e9liorer l\u2019usage des m\u00e9dicaments\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.unither-pharma.com\/fr\/#website\",\"url\":\"https:\/\/www.unither-pharma.com\/fr\/\",\"name\":\"Unither\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.unither-pharma.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.unither-pharma.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.unither-pharma.com\/fr\/#organization\",\"name\":\"Unither\",\"url\":\"https:\/\/www.unither-pharma.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.unither-pharma.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.unither-pharma.com\/wp-content\/uploads\/2026\/01\/logo-unither-pharmaceuticals-site-internet.png\",\"contentUrl\":\"https:\/\/www.unither-pharma.com\/wp-content\/uploads\/2026\/01\/logo-unither-pharmaceuticals-site-internet.png\",\"width\":514,\"height\":252,\"caption\":\"Unither\"},\"image\":{\"@id\":\"https:\/\/www.unither-pharma.com\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/UnitherPharma\",\"https:\/\/www.linkedin.com\/company\/unither-pharmaceuticals\/\",\"https:\/\/www.youtube.com\/channel\/UCHaTbYrnICFU1MiLwNsKjMA\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Les nouvelles formes d\u2019administration : un levier strat\u00e9gique pour am\u00e9liorer l\u2019usage des m\u00e9dicaments | Unither","description":"Les nouvelles formes d\u2019administration : un levier strat\u00e9gique pour am\u00e9liorer l\u2019usage des m\u00e9dicaments | Unither","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.unither-pharma.com\/fr\/publication\/technologies-de-liberation-des-medicaments-un-levier-cle-pour-offrir-un-avantage-concurrentiel\/","og_locale":"fr_FR","og_type":"article","og_title":"Les nouvelles formes d\u2019administration : un levier strat\u00e9gique pour am\u00e9liorer l\u2019usage des m\u00e9dicaments | Unither","og_description":"Les nouvelles formes d\u2019administration : un levier strat\u00e9gique pour am\u00e9liorer l\u2019usage des m\u00e9dicaments | Unither","og_url":"https:\/\/www.unither-pharma.com\/fr\/publication\/technologies-de-liberation-des-medicaments-un-levier-cle-pour-offrir-un-avantage-concurrentiel\/","og_site_name":"Unither","article_modified_time":"2026-03-18T14:52:08+00:00","twitter_card":"summary_large_image","twitter_site":"@UnitherPharma","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.unither-pharma.com\/fr\/publication\/technologies-de-liberation-des-medicaments-un-levier-cle-pour-offrir-un-avantage-concurrentiel\/","url":"https:\/\/www.unither-pharma.com\/fr\/publication\/technologies-de-liberation-des-medicaments-un-levier-cle-pour-offrir-un-avantage-concurrentiel\/","name":"Les nouvelles formes d\u2019administration : un levier strat\u00e9gique pour am\u00e9liorer l\u2019usage des m\u00e9dicaments | Unither","isPartOf":{"@id":"https:\/\/www.unither-pharma.com\/fr\/#website"},"datePublished":"2019-02-25T10:33:17+00:00","dateModified":"2026-03-18T14:52:08+00:00","description":"Les nouvelles formes d\u2019administration : un levier strat\u00e9gique pour am\u00e9liorer l\u2019usage des m\u00e9dicaments | Unither","breadcrumb":{"@id":"https:\/\/www.unither-pharma.com\/fr\/publication\/technologies-de-liberation-des-medicaments-un-levier-cle-pour-offrir-un-avantage-concurrentiel\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.unither-pharma.com\/fr\/publication\/technologies-de-liberation-des-medicaments-un-levier-cle-pour-offrir-un-avantage-concurrentiel\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.unither-pharma.com\/fr\/publication\/technologies-de-liberation-des-medicaments-un-levier-cle-pour-offrir-un-avantage-concurrentiel\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.unither-pharma.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Les nouvelles formes d\u2019administration : un levier strat\u00e9gique pour am\u00e9liorer l\u2019usage des m\u00e9dicaments"}]},{"@type":"WebSite","@id":"https:\/\/www.unither-pharma.com\/fr\/#website","url":"https:\/\/www.unither-pharma.com\/fr\/","name":"Unither","description":"","publisher":{"@id":"https:\/\/www.unither-pharma.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.unither-pharma.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.unither-pharma.com\/fr\/#organization","name":"Unither","url":"https:\/\/www.unither-pharma.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.unither-pharma.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.unither-pharma.com\/wp-content\/uploads\/2026\/01\/logo-unither-pharmaceuticals-site-internet.png","contentUrl":"https:\/\/www.unither-pharma.com\/wp-content\/uploads\/2026\/01\/logo-unither-pharmaceuticals-site-internet.png","width":514,"height":252,"caption":"Unither"},"image":{"@id":"https:\/\/www.unither-pharma.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/UnitherPharma","https:\/\/www.linkedin.com\/company\/unither-pharmaceuticals\/","https:\/\/www.youtube.com\/channel\/UCHaTbYrnICFU1MiLwNsKjMA"]}]}},"_links":{"self":[{"href":"https:\/\/www.unither-pharma.com\/fr\/wp-json\/wp\/v2\/publication\/31954","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.unither-pharma.com\/fr\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/www.unither-pharma.com\/fr\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/www.unither-pharma.com\/fr\/wp-json\/wp\/v2\/media?parent=31954"}],"wp:term":[{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.unither-pharma.com\/fr\/wp-json\/wp\/v2\/topic?post=31954"},{"taxonomy":"media_type","embeddable":true,"href":"https:\/\/www.unither-pharma.com\/fr\/wp-json\/wp\/v2\/media_type?post=31954"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}